Rezolute, Inc.
As of Oct 22, 2026, Rezolute is in Stage 3, the topping phase, now in week 6 (since Sep 16, 2026). It closed at $3.86, 64.7% below its 52-week high and above its 200-day average, which is rising.
Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is RZLT early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
RZLT among Biotechnology381st of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …381 | RZLT | Stage 3 · wk 6 | 20 | −3.5% |
Rezolute: quick answers
What stage is Rezolute in?
As of Oct 22, 2026, Rezolute (RZLT) is in Stage 3, the topping phase. It entered Stage 3 on Sep 16, 2026 and is in week 6. What the four stages mean
Is Rezolute in an uptrend?
Its uptrend has stalled. Rezolute is in Stage 3, the topping phase that follows an advance. It trades 0.4% above its 200-day average, which is rising.
How far is Rezolute from its 52-week high?
Rezolute closed at $3.86 on Oct 22, 2026, 64.7% below its 52-week high of $10.94. Its 52-week low is $1.40.
How has Rezolute performed over the past year?
As of Oct 22, 2026, Rezolute is down 56.4% over the past year and up 78.3% so far in 2026.
Which sector and industry is Rezolute in?
Rezolute is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.